Spotlight on Ravulizumab 4- side effects
Article No. 320 19 February 2020 Continuing in the series of news blogs about Ravulizumab, which so far has covered…
aHUS trials watch 9
Article No. 318 13 February 2020 The alliance has reported on the development of OMS721 made by Omeros before. It is…
Spotlight on Ravulizumab 3- developments
Article No. 317 6 February 2020 Just a few days ago, Alexion reported on its financial performance for 2019. Its net…
aHUS or TMA syndromes consensus
Article No. 316 1 February 2020 The alliance has featured what are known as aHUS consensus or status publications about the…
Spotlight on Ravulizumab 2- use in specific populations
Article No. 315 30 January 2020 Following on from the first spotlight on ravulizumab article about its dosing (click here to…
aHUS- when PEX is a success
Article No. 314 28 January 2020 One of the interests of the aHUS patient community is whether remission from treatment can continue…
Undetermined Significance yet aHUS
Article No. 313 26 January 2020 During the alliance's series of articles late last year about the renaming of aHUS we…
Global aHUS Registry: What’s it all About?
An article on FAQ regarding the aHUS global registry, including information gathered by atypical HUS patient advocates who represent the patient voice at the registry's Scientific Advisory Board meetings.
Spotlight on Ravulizumab 1- Dosing
Article No. 311 21 January 2020 Information about Ravulizumab cwvz has featured regularly on the alliance website during its development to…
- Go to the previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 23
- Go to the next page